Introduction
Patients with clinically manifest atherosclerotic arterial disease are generally considered to be at high risk of a recurrent cardiovascular events and the ESC guidelines considers all these patients to be at very high risk (VHR) of cardiovascular mortality.
1 By applying risk prediction algorithms such as the REACH 2 or SMART-risk score 3 however, it indeed becomes apparent that there is a wide distribution of actual risk for recurrent vascular events in patients with clinically manifest arterial disease: in the Second MAnifestations of ARTerial disease (SMART) study cohort a fifth of patients had a low risk (10-year risk <10%), two-fifth had a moderate risk (10-20% 10 year risk), a fifth were at high risk (20-30% 10 year risk) and a fifth was at highest risk (>30% 10 year risk of recurrent atherosclerotic cardiovascular disease (CVD). 3 Although most patients with CVD will benefit from lipid and blood pressure lowering therapy, identifying patients at very high risk for recurrent vascular events is of clinical relevance as more intensive risk factor management and novel, likely expensive, therapies may be considered. The number of patients at elevated risk of a recurrent cardiovascular event is likely to increase in the future due to improved revascularization options and secondary prevention strategies. Table S1 ) Although all patients with a history of CVD are classified as having very high risk according to the ESC 1, 6 and WHO 12 guidelines, the ACC/AHA guidelines classifies these patients to be at high risk and reserves the VHR label exclusive to patients who besides CVD have diabetes, current smoking, dyslipidaemia or progression of coronary artery disease. Current guidelines do not present absolute risk thresholds for the definition of very high risk. It is unknown which proportion of vascular patients meet the VHR criteria according to the ACC/AHA guidelines, and what their actual cardiovascular risk is. The aim of the present study is to describe the prevalence and actual risk of recurrent cardiovascular events according to the ACC/AHA VHR criteria, and to compare the performance of the ACC/AHA VHR criteria to other single very high risk factors in contemporary cohorts of patients with clinically manifest arterial disease.
Methods

Study populations
Data were used from two cohorts that included patients with a history of atherosclerotic CVD. The Second Manifestations of ARTerial disease (SMART) study is an ongoing prospective cohort study at the University Medical Center Utrecht, the Netherlands. A detailed description regarding study rationale and design has been published before. 13 For the present study, data was used from 7216 patients enrolled between September 1996 till March 2014 with either a history or a recent diagnosis of manifest atherosclerotic arterial disease. (Detailed description in Supplementary material online, 
Follow-up
In the SMART cohort, patients or the general practitioner were biannually asked to fill out a short questionnaire regarding hospitalization and outpatient clinic visits. An outcome committee of three staff members assessed whether outcomes occurred. In the REACH registry, outcomes of patients were annually reported by the local investigator and not adjudicated. The outcome of interest was recurrent major adverse cardiovascular events (MACE) a composite of stroke, myocardial infarction or cardiovascular mortality. (Detailed description in Supplementary material online, Table S2 ) In both cohorts, follow-up duration was defined as the period between enrollment and first cardiovascular event, death from any cause, date to loss of follow-up or the preselected date of March 2014 in SMART. In REACH, the initial follow-up was planned for 2 years, and shortly before that time point, an additional 2-year extension was proposed. Not all countries and sites participating in the 2-year follow-up cohort participated in the extension.
VHR criteria and selection of very high risk factors
All patients met the VHR criteria according to the ESC. 6 Patients with atherosclerotic CVD in combination with diabetes mellitus, current smoking or dyslipidaemia, and patients with a recent recurrent coronary event are considered as being at VHR by the American ACC/AHA 9, 10 guidelines. Risk factors for very high risk were identified based on current guidelines and literature. (Detailed description in Supplementary material online, Table S3 ) The first four very high risk factors were based on the 4 ACC/AHA VHR criteria. Based on the SMART-risk score 3 and from previous findings in REACH 2 , more very high risk factors on specific types of vascular disease; polyvascular disease (i.e. atherosclerotic disease in two or more vascular beds), peripheral artery disease, abdominal aortic aneurysm (AAA), congestive heart failure and presence of atrial fibrillation were created. The very high risk factor 'recent progression of vascular disease' was adopted from the ACC/AHA VHR criteria, except that the most recent event was not limited to coronary artery disease, but could be vascular disease at any location. In addition, we considered (severe) obesity, therapy resistant hypertension, hyperlipidaemia or chronic kidney disease, as suggested by the ESC guidelines 1 as possible very high risk factors.
Data analyses
Single imputation methods were used to reduce missing covariate data. If a patient had multiple events, the first recorded event was used in the analyses.
. First, prevalence and incidence rates of recurrent MACE per 100 person years (PY) were calculated in both cohorts, (i.e. for patients meeting the ESC VHR criteria) and for patients who met the ACC/AHA VHR criteria and for those who did not meet the VHR criteria. Incidence rates and 95% confidence intervals (CI) were calculated with a Poisson regression model and were stratified for sex and age, since these are important drivers of risk.
Second, to compare performance of the ACC/AHA VHR criteria to other very high risk factors, incidence rates, C-statistics and NRI's were all taken into account. Incidence rates were calculated for recurrent MACE for all previously describe very high risk factors. Since there is no single reference group, incidence rates were not adjusted for age or sex. The analyses were repeated in patients younger than 70 years, to evaluate whether very high risk factors were robust and did not only select the very old. A sensitivity analysis was done after exclusion of patients with atrial fibrillation (in SMART and REACH) and congestive heart failure in REACH, because this was unknown in the SMART-study. Discrimination, (the ability to distinguish between patients who will get the disease and patients who will not get the disease) was assessed by calculating Harrell's C(concordance)-statistic 18, 19 for each very high risk factor and for the ACC/AHA VHR criteria. To quantify the amount of patients who would be correctly reclassified as being at very high risk of recurrent MACE when a single risk factor was used instead of the ACC/AHA VHR criteria, a net reclassification index (NRI) was calculated. NRI's were stratified according to event status, 20 which is described into more details in the Supplementary material online. Third, the performance of the ACC/AHA criteria was compared to an existing risk prediction algorithm, by plotting the distribution of predicted risk of recurrent MACE (calculated with the SMART-risk score) for patients who did and did not meet the ACC/AHA VHR criteria. Predicted 10-year risk was also plotted for a selection of patients aged >70 years, a selection of patients who met the ACC/AHA VHR criteria and in patients who did not meet the ACC/AHA VHR criteria. Statistical analyses were performed using R-3.2 for Windows (http://cran.r-project.org/).
Results
Baseline patient characteristics
Patients in SMART had an average age of 60.1 ± 10.3 years and a total of 60% of the population had a history of coronary artery disease, followed by cerebrovascular disease (29%), peripheral artery disease (19%), AAA (9%) and 15% had vascular disease in multiple locations. Patients in REACH were on average older (66.6 ± 8.9 years and the majority of the patients had a history of coronary artery disease (73%), followed by cerebrovascular disease (36%), peripheral artery disease (17%), AAA (3%) and 25% had polyvascular disease. In the SMART cohort, 66% used statins at baseline and in REACH this was 70% ( Table 1) . The percentage of patients using statins, blood pressure lowering therapy or anti-platelets or anti-coagulants remained the same in both cohorts when only selecting patients who met the ACC/AHA VHR criteria.
Prevalence and actual risk of recurrent MACE
In the SMART cohort, 1185 MACE were recorded during a median follow-up time of 6.5 years (interquartile range (IQR) 3.4-9.9 years). On average the incidence of recurrent MACE was 2.4/100PY (95% CI 2.3-2.5/100PY) and 57% of the SMART population met the ACC/ AHA criteria of VHR (incidence 2.7/100PY, 95% CI 2.5-2.9/100PY).
In REACH, the median follow-up time was 1.8 years (IQR 1.5-1.9), 2773 MACE occurred and the incidence for recurrent MACE was 5.1/100PY (95% CI 5.0-5.3/100PY). A total of 64% of the REACH participants met the AHA/ACC criteria for VHR and on average the incidence for recurrent MACE was 5.9/100PY (95% CI 5.7-6./100PY) in these patients. Patients not meeting the ACC/AHA criteria for VHR had an incidence of 2.0/100PY in SMART and 3.9/100PY in REACH. There was a statistically significant difference in incidence rates between patients meeting the ACC/AHA VHR criteria and those who did not meet the criteria in both cohorts. Incidence rates were higher in older age categories and standardization for age and sex did not influence the incidence in SMART nor in REACH (Figure 1 and 2) .
Incidence rates of recurrent MACE according to the very high risk factors
In Figure 2 (and Supplementary material online, Table S4 ), incidence rates of recurrent MACE for single very high risk factors, ranked according to highest to lowest incidence in REACH, are presented next to the incidence of patients who did and did not meet the ACC/AHA VHR criteria and the overall incidence (which corresponds to patients at VHR according to the ESC).
Highest incidence for recurrent MACE were found in patients with an eGFR <45 mL/min/1.73m 2 (incidence 6.9/100PY, 95% CI 5. Data are displayed as mean (±SD), n (%) or median (inter-quartile range) which are marked * NA: not available, data missing in REACH Registry, eGFR was calculated according to the CKD-EPI formula.
Identification of vascular patients at very high risk Figure 1 Crude and age stratified incidence rates with 95% confidence intervals of recurrent MACE in the total study population and according to the ACC/AHA very high risk definition. MACE, major adverse cardiovascular events; VHR ACC/AHA, selection of patients defined as being at very high risk according to the ACC/AHA guidelines 9,10 which is described in more detail in Supplementary material online, Table S1 . Figure 2 Performance of very high risk factors and the ACC/AHA VHR criteria. P-value for difference in IR's between ACC/AHA VHR and not ACC/AHA VHR in both cohorts was <0.001. IR/100PY, incidence rate per 100 person years; NRI, net reclassification index; eGFR<45, estimated glomerular filtration rate <45 mL/min/1.73m 2 ; progression of CAD, recent progression of coronary artery disease; AAA or PAD, aneurysm of abdominal aorta or peripheral artery disease; ACC/AHA VHR, very high risk according to the ACC/AHA guidelines 9, 10 ; ESC VHR, very high risk according to the European Society of Cardiology 1, 6 ; since all patients had manifest arterial disease, all were at very high risk according to the ESC. A more detailed description of these definitions and very high risk factors are found in Supplementary material online, Table S1 and more results on performance in Supplementary material online, Table S4 In a selection of patients aged <70 years (Supplementary material online, Table S5 ), incidence of recurrent MACE on average were slightly lower when compared with the total study population; 1.9/ 100PY in SMART and 4.3/100PY in REACH. Very high risk factors with highest event rates remained eGFR <45 (incidence 5.4/100PY in SMART and 9.1/100PY in REACH), polyvascular disease (incidence 4.0/100PY in SMART and 6.8/100PY in REACH), in REACH progression of coronary artery disease (7/2/100PY) and in SMART diabetes (IR 2.9/100PY and in REACH 5.2/100PY).
After excluding patients with congestive heart failure or atrial fibrillation (Supplementary material online, Table S6 ), incidence of recurrent MACE were comparable to the total study population in SMART (incidence 2.4/100PY) and lower in REACH (incidence 4.2/100PY). eGFR <45 (6.9/100PY in SMART and 7.6 in REACH) and polyvascular disease (4.9/100PY in SMART and 6.2/100PY in REACH) remained the risk factors with highest incidence rates of recurrent MACE.
Performance of the ACC/AHA VHR criteria and other very high risk factors
The ACC/AHA VHR criteria had poor to moderate discrimination in identifying patients who developed a recurrent cardiovascular event Table S5 ) After excluding patients with atrial fibrillation or heart failure, C-statistics in SMART and REACH did not change compared with the total study population (Supplementary material online, Table  S6 ). The single risk factors polyvascular disease and age >70 led to improved reclassification of patients at very high risk of a recurrent event during follow-up when compared with using the ACC/AHA VHR criteria (Figure 2) .
Distribution of predicted 10-year risk of recurrent MACE
In Figure 3 , the distribution of predicted 10-year risk of recurrent MACE (calculated with the SMART risk score 3 ) were plotted in SMART and REACH. In both cohorts, the distribution of risk was slightly shifted to the left in patients who did not meet the ACC/AHA VHR criteria when compared to patient who did met the ACC/AHA VHR criteria. Predicted 10-year risk of recurrent MACE was calculated with the SMART-risk score 3 and 30% predicted 10-year risk is indicated with a dashed red line. Proportion of patients with 10-year predicted risk >30% was for A) 25% in SMART and 30% in REACH, B) 68% in SMART and 58% in REACH, C) 29% in SMART and 33% in REACH and D) 19% both in SMART and REACH.
Identification of vascular patients at very high risk
Distributions of predicted 10-year risk in SMART and REACH were also plotted next to each other in the total study populations and in selections of patients. (Supplementary material online, Figure  S1 ). The proportion of patients with a predicted 10-year risk > _30% was much higher in patients aged > _70 years (68% in SMART and 58% in REACH) when compared to the overall study populations (25% in SMART and 30% in REACH). In patients at very high risk according to the ACC/AHA criteria, the proportion of patients with >30% 10-year risk was 29% in SMART and 33% REACH, while in patients who were not at VHR according to the ACC/AHA, this was 19% both in SMART and REACH.
Discussion
In the present study, it is shown that the actual risk of recurrent cardiovascular events in patients with clinically manifest atherosclerotic arterial disease on average is high. About 60% of patients with vascular disease were considered to be at VHR according to the AHA/ ACC criteria, with slightly higher actual risk of recurrent MACE.
Risk distribution plots show that two third of patients meeting the ACC/AHA VHR criteria had an expected 10-year risk prediction of recurrent MACE <30%. Fulfilling one of the following single very high risk factors; eGFR <45, polyvascular disease, or age >70 years performs as well as or event better at VHR determination as the ACC/ AHA VHR criteria, in terms of discriminative power and accurate reclassification.
Identifying patients at VHR, defined as > _30% 10-year risk for recurrent cardiovascular events or those in the top quarter of the risk distribution is be of clinical importance, since intensive lifestyle programs or further LDL-cholesterol reduction with novel, often expensive therapies may be considered. 21, 22 Patients at VHR may have more to gain from treatment while patients at lower risk may not derive sufficient benefit to overcome the costs and harms of treatment. Depending on country and setting, broader or stricter VHR definitions may be suitable based on resources and cost-effectiveness. 23 Clinical criteria of VHR could also be used as inclusion criteria for clinical trials evaluating vascular risk reduction interventions, thus including patients with a high unmet medical need. The present study shows that differentiating patients at highest risk from an already high risk population is difficult. Ideally a simple set of clinical criteria, routinely available in clinical practice, would have high enough discriminatory power to identify VHR patients. Based on our study, we conclude that the current ACC/AHA VHR criteria do not include the strongest predictors of risk in evaluating patients with manifest atherosclerotic arterial disease and alternative criteria are an eGFR <45, a history of polyvascular disease or age >70 years. On the other hand, it also appears unlikely that a limited set of dichotomous variables will hold the same amount of information and will have comparable discriminative power as sophisticated risk score algorithms.
We found the highest event rates in patients with CVD with concomitant chronic kidney disease. Patients with chronic kidney disease have a 2-4 times increased risk of cardiovascular events and as kidney function further deteriorates, morbidity, and mortality rates further increase. 24 Higher event rates were also found in patients with polyvascular disease and/or progression of coronary artery disease, which shows that risk of recurrent MACE increases with advancing stages of manifest atherosclerosis. Interestingly, the lowest event rates were found in patients with CVD and obesity. This could have been caused by a selection of younger patients (average age of severely obese patients in SMART was 55 years and in REACH 64 years). Although based on unadjusted incidence rates, another explanation could be the 'obesity paradox', which is the hypothesis that obesity has a favorable effect on cardiovascular morbidity and mortality in patients with chronic disease, such as prevalent cardiovascular disease. 25, 26 Except for progression of coronary artery disease, the single VHR clinical criteria of ACC/AHA had relative low incidence rates which could be due to that these predictors also selected younger patients (average age current smokers was 56 and 62 years in SMART and REACH and for dyslipidaemia 58 and 65 years, respectively) or because these risk factors are modifiable and patients may have quit smoking or received more intensive (lipid lowering) therapy during follow-up, leading to lower absolute risks. Age is an important driver of risk of recurrent cardiovascular events and thus stratifying risk in a population may simply be similar to stratifying risk by age. Analyses therefore were repeated in patients aged < _70 years, which showed overall a slightly lower risk when compared with the total study population. Patients with an eGFR <45 however still had highest incidence of recurrent MACE. Incidence rates in patients with polyvascular disease were slightly lower, an indication that these patients on average were older at baseline.
Participants in REACH overall had a higher risk of recurrent cardiovascular events when compared with the SMART population which is most likely due to the fact that patients in REACH had different ethnic backgrounds, more extensive vascular disease and comorbidities such as DM and chronic kidney disease and on average, were 5 years older. Incidence rates and performance results of the ACC/ AHA VHR criteria and the new VHR criteria however, were consistent in both cohorts. This provides some ground for generalizability, although results should not be extrapolated to other ethnic groups without caution since all participants in SMART and 62% in REACH registry were white.
Strengths of this study are its observational prospective design, reflecting clinical practice in a large number of patients with a variety of atherosclerotic disease manifestations (cerebrovascular, coronary artery, peripheral artery disease, and AAA). Study limitations should also be considered. The selection of very high risk factors in SMART and REACH was based on availability in these cohorts. In SMART there was limited information on congestive heart failure and atrial fibrillation and in the REACH Registry, there was no information on HDL-C and LDL-C measurements.
In conclusion, within the group of patients with clinically manifest arterial disease, single very high risk factors or simple criteria (such as the ACC/AHA VHR criteria) have limited discriminative power to identify patients at highest risk of recurrent MACE. Implementation of risk prediction algorithms in secondary prevention is necessary to improve identification of patients at highest risk and might lead to better allocation of resources.
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